Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.
复制标题
高剂量白介素 2 和淋巴因子激活杀伤细胞治疗霍奇金病和非霍奇金淋巴瘤的 II 期试验。
DOI：
10.1097/00002371-199106000-00008
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Hawkins,MJ
中科院分区：
文献类型：
--
作者：
Margolin,KA;Aronson,FR;Sznol,M;Atkins,MB;Ciobanu,N;Fisher,RI;Weiss,GR;Doroshow,JH;Bar,MH;Hawkins,MJ
白细胞介素-2 （IL-2）联合淋巴因子活化杀伤细胞（LAK）治疗肾癌和恶性黑色素瘤具有抗肿瘤活性。为了探索这种疗法在霍奇金病和非霍奇金淋巴瘤中的活性，外IL-2/LAK工作组（ILWG）采用高剂量IL-2和自体LAK细胞两种方案治疗了27例患者。12例何杰金氏病患者中有2例经历了持续6周和12周的部分反应。非霍奇金淋巴瘤患者无应答（p= NS）。治疗的毒性与ILWG在实体瘤中IL-2/LAK试验中报告的毒性相似，包括短暂的血液动力学、心肺、肾脏和肝功能障碍、皮疹、发烧和流感样症状。鉴于低反应率和这些反应持续时间短，我们不推荐本文报道的方案用于霍奇金病或非霍奇金淋巴瘤的进一步研究
Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin's disease and non-Hodgkin's lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin's disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin's lymphoma responded (p= NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin's disease or non-Hodgkin's lymphomas